Latest News

Page 2 of 2612345...1020...Last »

April 15, 2017

New Sustained Delivery Method for Lucentis

Posted in: Latest News, Research and Developments

Genentech, Inc. is testing a less-invasive method of delivery of their anti-VEGF drug Lucentis into the eyes of patients with wet AMD. Currently, anti-VEGF treatments require regular monthly or bi-monthly injections into the back of the eye, which can be taxing on patients’ time and stress level. The new method utilizes a timed release capsule
read more »

April 2, 2017

Brain “rewires” itself to enhance other senses in blind people

Posted in: Latest News, Research and Developments

A common belief that blind people possess unusually heightened non-visual senses now may be more than just a belief. Credit: Bauer et al. PLOS ONE 2017 A new study led by Massachusetts Eye and Ear researchers has found that the brains of those who are born blind make new connections in the absence of visual information.
read more »

March 27, 2017

Once-Promising Study of Encapsulated Cell Technology Halted

Posted in: Latest News, Research and Developments

Researchers have found no significant difference between patients implanted with capsules manufacturing the drug NT-503 and patients receiving anti-VEGF drug injections. As reported on this site in 2015, Neurotech Pharmaceuticals, Inc. announced a Phase 2 clinical study of NT-503 Encapsulated Cell Therapy (ECT) for the treatment of wet age-related macular degeneration (AMD). The study planned
read more »

March 17, 2017

Is Stem Cell Therapy Dangerous?

Posted in: Latest News, Research and Developments

Commentary by Dan Roberts, Editor Living Well With Low Vision The low vision community has been shaken this past week by news of three patients whose vision was damaged by stem cell treatment at a Florida clinic in 2015. There is good reason for concern, but not about the future of stem cell therapy for
read more »

March 13, 2017

OpRegen® for Dry-AMD in Trials

Posted in: Latest News, Research and Developments

BioTime, Inc. is expanding its ongoing Phase I/IIa clinical trial for OpRegen® for treatment of dry AMD. by naming the first two sites that will treat patients in the U.S. Adi Mohanty, Co-Chief Executive Officer of BioTime, said, “We are honored to be working with two of the leading U.S. clinicians in ophthalmology, Dr. David
read more »

March 8, 2017

Further Evidence of the Value of In-Home Occupational Therapy

Posted in: Latest News, Low Vision Rehabilitation, Research and Developments

A new study, published in the March 8 edition of Investigative Ophthalmology & Visual Science, has concluded that low-vision patients who improve in their daily living activities through at-home training with an occupational therapist (OT) have less severe symptoms of depression than similar patients who did not receive such training. Using outcomes from a recently
read more »

February 27, 2017

Bright Flash Retinal Photography–a Thing of the Past

Posted in: Latest News, Therapies, Treatments, and Procedures

by Dan Roberts (Macular Degeneration Support) and Liz Trauernicht (Macular Degeneration Foundation) OCT and nonmydriatic technologies are lessening discomfort and risk of eye exams. MD Support and MD Foundation communicate with thousands of patients who undergo periodic eye exams for diagnosis and treatment of macular degeneration, glaucoma, diabetic retinopathy, and other chronic diseases. Many have
read more »

February 15, 2017

Another Anti-VEGF Drug Falls Short

Posted in: Latest News, Research and Developments

by Dan Roberts We announced here in December 2016 that Fovista, Ophthotech’s once-promising experimental drug for treatment of wet macular degeneration, failed to show positive results in Phase 3 trials, resulting in a discontinuance of the research. Now, Ohr Pharmaceuticals has announced temporary suspension of a clinical study for its drug candidate, Squalamine, an eye
read more »

January 27, 2017

Trials beginning for Emixustat Treatment of Stargardt Disease

Posted in: Latest News, Research and Developments

Acucela has announced that the first patient has enrolled in a study to evaluate emixustat hydrochloride (“emixustat”) in subjects with Stargardt disease. Approximately 30 subjects will be enrolled at 4 to 6 clinical sites in the United States, with subjects taking oral doses of the drug once daily in the evening for one month. Emixustat
read more »

January 22, 2017

“How soon will my good eye go bad?”

Posted in: Latest News, Research and Developments

This is commonly-asked by people affected with unilateral age-related macular degeneration (AMD). AMD is a chronic and progressive disease, and the chances are good that it will eventually affect both eyes. The question about when that will happen has been addressed by a three-continent study published in January 2017 by the British Journal of Ophthalmology. Researchers
read more »

Page 2 of 2612345...1020...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann